DE69327542T2 - Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung - Google Patents

Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung

Info

Publication number
DE69327542T2
DE69327542T2 DE69327542T DE69327542T DE69327542T2 DE 69327542 T2 DE69327542 T2 DE 69327542T2 DE 69327542 T DE69327542 T DE 69327542T DE 69327542 T DE69327542 T DE 69327542T DE 69327542 T2 DE69327542 T2 DE 69327542T2
Authority
DE
Germany
Prior art keywords
microsphere
antipsychotic
biocompatible polymer
dispense
microball
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69327542T
Other languages
English (en)
Other versions
DE69327542D1 (de
Inventor
Shigemi Kino
Tomonori Osajima
Hiroaki Mizuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18255017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69327542(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Welfide Corp filed Critical Welfide Corp
Publication of DE69327542D1 publication Critical patent/DE69327542D1/de
Application granted granted Critical
Publication of DE69327542T2 publication Critical patent/DE69327542T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
DE69327542T 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung Revoked DE69327542T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33244192 1992-11-17
PCT/JP1993/001673 WO1994010982A1 (en) 1992-11-17 1993-11-15 Sustained-release microsphere containing antipsychotic and process for producing the same

Publications (2)

Publication Number Publication Date
DE69327542D1 DE69327542D1 (de) 2000-02-10
DE69327542T2 true DE69327542T2 (de) 2000-07-06

Family

ID=18255017

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69327542T Revoked DE69327542T2 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
DE0669128T Pending DE669128T1 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0669128T Pending DE669128T1 (de) 1992-11-17 1993-11-15 Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.

Country Status (11)

Country Link
US (2) US5656299A (de)
EP (1) EP0669128B1 (de)
KR (1) KR100333115B1 (de)
AT (1) ATE188375T1 (de)
CA (1) CA2148823C (de)
DE (2) DE69327542T2 (de)
DK (1) DK0669128T3 (de)
ES (1) ES2077547T3 (de)
GR (2) GR960300020T1 (de)
PT (1) PT669128E (de)
WO (1) WO1994010982A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
DK0729353T4 (da) * 1993-11-19 2012-10-01 Alkermes Inc Fremstilling af bionedbrydelige mikropartikler som indeholder et biologisk aktivt middel
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
EP0733368A1 (de) * 1995-03-24 1996-09-25 Eli Lilly And Company Granulatformulierungen von Olanzapin
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
ATE223206T1 (de) * 1996-05-07 2002-09-15 Alkermes Inc Verfahren zur herstellung von mikropartikeln
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
AU737078C (en) * 1996-05-24 2002-05-02 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6854841B1 (en) * 1998-04-17 2005-02-15 Elesys, Inc. Point-of-incidence ink-curing mechanisms for radial printing
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
GB9817078D0 (en) * 1998-08-05 1998-10-07 Habib Nagy A Device for liver surgery
NZ510208A (en) * 1998-09-30 2003-04-29 Lilly Co Eli Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
CA2346001C (en) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
ES2243232T3 (es) * 1999-02-23 2005-12-01 Angiotech International Ag Composiciones y metodos para mejorar la integridad de cavidades y vias corporales comprometidas.
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
CA2431285A1 (en) * 2000-12-13 2002-06-20 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
AU2002324447B2 (en) 2001-06-22 2006-06-29 Durect Corporation Zero-order prolonged release coaxial implants
ATE552017T1 (de) 2001-06-29 2012-04-15 Medgraft Microtech Inc Biologisch abbaubare injizierbare implantate und verwandte herstellungs- und verwendungsmethoden
EP1275378B1 (de) 2001-07-10 2009-04-15 Canon Kabushiki Kaisha Partikel auf Basis von Polyhydroxyalkanoat und Verfahren zu deren Herstellung
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US6699963B2 (en) * 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
JP2005531521A (ja) * 2002-03-26 2005-10-20 テバ ファーマシューティカル インダストリーズ リミティド ドラッグ微粒子
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2516339A1 (en) * 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersing agent for sustained-release preparation
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
SI2409707T1 (sl) 2004-04-15 2015-07-31 Alkermes Pharma Ireland Limited Naprava s podaljšanim sproščanjem na osnovi polimerov
ES2527286T3 (es) * 2004-04-30 2015-01-22 Abraxis Bioscience, Llc Microesferas de liberación sostenida y métodos de fabricación y uso de las mismas
ITMI20042232A1 (it) * 2004-11-19 2005-02-19 Unihart Corp Composizione farmaceutica contenente clozapina
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
MX362908B (es) * 2005-07-18 2019-02-21 Univ Pennsylvania Implantes que contienen fármacos y métodos de uso de los mismos.
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7811604B1 (en) * 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
CN101541313A (zh) * 2006-10-05 2009-09-23 万能药生物有限公司 可注射的储库组合物及其制备方法
JP2010522196A (ja) * 2007-03-22 2010-07-01 アルカームズ，インコーポレイテッド コアセルベーション工程
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
UA96342C2 (en) 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
US9161943B2 (en) * 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
EA023177B1 (ru) 2009-06-09 2016-05-31 Неуронано Аб Микроэлектрод и пучок микроэлектродов, содержащие устройства для высвобождения лекарственных средств в ткани
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL3199146T3 (pl) 2011-04-25 2020-03-31 Shan Dong Luye Pharmaceutical Co., Ltd. Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
CN105163719B (zh) 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
KR101738127B1 (ko) * 2014-08-08 2017-05-22 (주)비씨월드제약 약물 함유 서방성 미립자의 제조 방법
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
AU2020312361A1 (en) * 2019-07-12 2022-03-03 G2Gbio, Inc. Long-lasting formulation containing rivastigmine, and method for preparing same
CN111991397B (zh) * 2020-10-13 2021-09-10 深圳善康医疗健康产业有限公司 一种氟哌噻吨美利曲辛微球及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
FR2534139B1 (fr) * 1982-10-07 1986-08-29 Laruelle Claude Nouvelle forme galenique du sulpiride, son procede de preparation et medicament comprenant cette nouvelle forme
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
EP0669128A1 (de) 1995-08-30
CA2148823A1 (en) 1994-05-26
DE69327542D1 (de) 2000-02-10
KR100333115B1 (ko) 2002-12-02
DK0669128T3 (da) 2000-06-19
EP0669128B1 (de) 2000-01-05
KR950703936A (ko) 1995-11-17
CA2148823C (en) 1999-03-09
US5871778A (en) 1999-02-16
GR960300020T1 (en) 1996-03-31
WO1994010982A1 (en) 1994-05-26
PT669128E (pt) 2000-06-30
ATE188375T1 (de) 2000-01-15
DE669128T1 (de) 1996-03-14
GR3033016T3 (en) 2000-08-31
ES2077547T1 (es) 1995-12-01
EP0669128A4 (de) 1996-09-25
US5656299A (en) 1997-08-12
ES2077547T3 (es) 2000-06-16

Similar Documents

Publication Publication Date Title
DE69327542D1 (de) Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
Devlin et al. Healing of tooth extraction sockets in experimental diabetes mellitus
DE69819694T2 (de) Subkutan oder intradermal injizierbares implantat in der plastischen oder wiederherstellenden chirurgie
DE3778244D1 (de) Oestradiol-implantat und verfahren zu seiner herstellung.
IL78826A0 (en) Sustained release pharmaceutical compositions incorporating degradable delivery system of drugs
EP0301856A3 (en) Delivery system
CA2011637A1 (en) Compositions for the sustained-release of chlorhexidine
ITPD910229A1 (it) Tessuto non tessuto essenzialmente costituito da derivati dell'acido ialuronico
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
ATE125158T1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
IE882727L (en) Sustained release pharmaceutical compositions
ATE288258T1 (de) Biodegradierbare polymerzusammensetzung
KR960705512A (ko) 생체적합성 안과용 삽입체(biocompatible ocular implants)
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
US20110244006A1 (en) Microsphere skin treatment
FR2686250B1 (de)
DE69703430T2 (de) Polymere mit kontrolliertem physikalischen zustand und bioerodierbarkeit
DE3889933D1 (de) Perorale Arzneimittelzubereitung mit verzögerter Wirkstofffreigabe.
DO et al. Optimizing Injections of Poly–L–Lactic Acid: The 6-Step Technique
ATA223591A (de) Verfahren zur herstellung einer zur kontinuierlichen und kontrollierten abgabe eines natürlichen oder synthetischen peptids bestimmten pharmazeutischen zusammensetzung, insbesondere in form von mikrokapseln bzw. implantaten
JPS6450824A (en) Improved immunity for mammals

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: WELFIDE CORP., OSAKA, JP

8327 Change in the person/name/address of the patent owner

Owner name: MITSUBISHI PHARMA CORP., OSAKA, JP

8331 Complete revocation